Vnitr Lek 2013, 59(8):743-746

Colitis precipitated by Clostridium difficile - a serious current problem

P. Husa
Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Husa, CSc.

Clostridium difficile is currently considered a significant cause of nosocomial infection. The probability of a colonisation of hospitalised patients rises with the length of their stay in hospital and depends on the local epidemiologic situation. Interdisciplinary collaboration is the foundation of the effort to limit the development of this very serious, often fatal disease. The basic element is a rational antibiotic therapy which builds on the knowledge that the administration of antibiotics, even though based on a correct indication, may be fatal in an environment which is massively contaminated by spores of Clostridium difficile. Consequently, the high-risk antibiotics (such as aminopenicillins, fluoroquinolones or cefalosporins) should be administered only in such cases where they cannot be substituted by antibiotics with a lower risk of CDI.

Keywords: Clostridium difficile infection; vancomycin; metronidazole; fidaxomicin

Received: February 20, 2013; Published: August 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P. Colitis precipitated by Clostridium difficile - a serious current problem. Vnitr Lek. 2013;59(8):743-746.
Download citation

References

  1. Savage DC. The microbial flora in the gastrointestinal tract. Prog Clin Biol Res 1981; 77: 893-908.
  2. Bartlett JG, Chang TW, Gurwith M et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298: 531-534. Go to original source... Go to PubMed...
  3. Larson HE, Price AB, Honour P et al. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978; 1: 1063-1066. Go to original source... Go to PubMed...
  4. Cartman ST, Heap JT, Kuehne SA et al. The emergence of "hypervirulence" in Clostridium difficile. Int J Med Microbiol 2010; 300: 387-395. Go to original source... Go to PubMed...
  5. Bishop KD, Castillo JJ. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 2012; 53: 1617-1619. Go to original source... Go to PubMed...
  6. Státní zdravotní ústav, databáze Infekce v ČR - EPIDAT. Dostupné na: www.szu.cz.
  7. Vojtilová L, Freibergerová M, Juránková J et al. Analýza souboru pacientů s onemocněním vyvolaným toxinem Clostridium difficile hospitalizovaných na Klinice infekčních chorob v Brně v letech 2007-2010. Klin Mikrobiol Inf Lék 2011; 17: 208-213.
  8. Vojtilová L, Pýchová M, Freibergerová M et al. Rizikové faktory rekurentního a těžkého průběhu kolitidy vyvolané infekcí Clostridium difficile. Vnitř Lék 2013; 59: 23-30. Go to PubMed...
  9. Beneš J, Husa P, Nyč O. Doporučený postup diagnostiky a léčby kolitidy vyvolané Clostridium difficile. Klin Mikrobiol Inf Lék 2012; 18: 160-167.
  10. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-1079.
  11. Bauer MP, Notermans DW, van Benthem BH et al. ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73. Go to original source... Go to PubMed...
  12. Nyč O, Pituch H, Matějková J et al. Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland. Lancet 2011; 377: 1407. Go to original source... Go to PubMed...
  13. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-431. Go to original source... Go to PubMed...
  14. Polák P, Freibergerová M, Juránková J et al. První zkušenosti s fekální bakterioterapií v léčbě relabující pseudomembranózní kolitidy způsobené Clostridium difficile. Klin Mikrobiol Inf Lék 2011; 17: 214-217.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.